Niikura, Naoki http://orcid.org/0000-0001-6732-8527
Yamanaka, Takashi
Nomura, Hironori
Shiraishi, Kazuhiro
Kusama, Hiroki
Yamamoto, Mitsugu
Matsuura, Kazuo
Inoue, Kenichi
Takahara, Sachiko
Kita, Shosuke
Yamaguchi, Miki
Aruga, Tomoyuki
Shibata, Nobuhiro http://orcid.org/0000-0001-8647-5098
Shimomura, Akihiko
Ozaki, Yuri
Sakai, Shuji
Kiga, Yoko
Izutani, Tadahiro
Shiosakai, Kazuhito
Tsurutani, Junji
Funding for this research was provided by:
Daiichi Sankyo Company (Not applicable)
Article History
Received: 10 March 2023
Accepted: 13 September 2023
First Online: 11 October 2023
Competing interests
: N.N. reports consulting or advisory roles for AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd; and has received lecture fees from AstraZeneca K.K., Eisai Co., Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Nippon Kayaku Co., Ltd; and research funding from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Nippon Kayaku Co., Ltd. T.Y. has received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., and Pfizer Japan Inc. K.I. has received research funding from Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Ono Pharmaceutical Co., Ltd. MYamaguchi has received speakers’ bureau from Pfizer Japan Inc., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MEDICON Co., Ltd., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd. TA has received speakers’ bureau from Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eli Lilly Japan K.K., and AstraZeneca K.K. N.S. reports consulting or advisory roles for Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd; and has received speakers’ bureau from Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd.; and research funding from Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and MSD K.K. JT reports consulting or advisory roles for Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Eisai Co., Ltd., Eli Lilly Japan K.K., and Seagen Inc.; and has received speakers’ bureau from Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., and Kyowa Kirin Co., Ltd.; and research funding from Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Eisai Co., Ltd., Eli Lilly Japan K.K., Seagen Inc., Kyowa Kirin Co., Ltd., Sant Joan de Déu Research Foundation, and West Japan Oncology Group. YK, TI, and KShiosakai are employees of Daiichi Sankyo Co., Ltd. H.N., K. Shiraishi, H.K., M. Yamamoto, K.M., S.T., S.K., A.S., Y.O., and S.S. have no conflicts of interest to disclose.